Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

PURPOSE: NALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, a reversible dual TKI, plus capecitabine (L+C) in patients with cent...

Descripción completa

Detalles Bibliográficos
Autores principales: Saura, Cristina, Oliveira, Mafalda, Feng, Yin-Hsun, Dai, Ming-Shen, Chen, Shang-Wen, Hurvitz, Sara A., Kim, Sung-Bae, Moy, Beverly, Delaloge, Suzette, Gradishar, William, Masuda, Norikazu, Palacova, Marketa, Trudeau, Maureen E., Mattson, Johanna, Yap, Yoon Sim, Hou, Ming-Feng, De Laurentiis, Michelino, Yeh, Yu-Min, Chang, Hong-Tai, Yau, Thomas, Wildiers, Hans, Haley, Barbara, Fagnani, Daniele, Lu, Yen-Shen, Crown, John, Lin, Johnson, Takahashi, Masato, Takano, Toshimi, Yamaguchi, Miki, Fujii, Takaaki, Yao, Bin, Bebchuk, Judith, Keyvanjah, Kiana, Bryce, Richard, Brufsky, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499616/
https://www.ncbi.nlm.nih.gov/pubmed/32678716
http://dx.doi.org/10.1200/JCO.20.00147

Ejemplares similares

Ejemplares similares